Peter Debry, MD
Ophthalmology · Henderson, NVNPI 1831137991
Payments from drug & device makers
Across 261 payments — averaging $1238.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$169K
- Novartis$123K
- Kala Pharmaceuticals, Inc.$24K
- Johnson & Johnson Surgical Vision, Inc.$2K
- Ivantis, Inc$1K
- Alcon$846
- plus $3K from 19 others
What the payments were for
- Consulting fees$2,50024%
- Travel & lodging$1,43214%
- Food & beverage$6,36262%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 96 | $169,224 |
| Novartis | 4 | $122,809 |
| Kala Pharmaceuticals, Inc. | 10 | $23,966 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $1,810 |
| Ivantis, Inc | 6 | $1,106 |
| Alcon | 28 | $846 |
| Glaukos Corporation | 36 | $834 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 17 | $376 |
| Sight Sciences, Inc. | 6 | $323 |
| Aerie Pharmaceuticals, Inc. | 12 | $314 |
| Rxsight Inc | 3 | $251 |
| Bausch & Lomb Americas Inc. | 8 | $222 |
| Nova Eye, Inc. | 1 | $184 |
| Microsurgical Technology, Inc. | 1 | $160 |
| Amgen | 3 | $158 |
| Harrow Eye, LLC | 1 | $136 |
| Thea Pharma Inc. | 8 | $131 |
| Sun Pharmaceutical Industries Inc. | 4 | $83 |
| Oyster Point Pharma, Inc. | 2 | $52 |
| Dompe US, Inc. | 2 | $51 |
| Staar Surgical Company | 2 | $33 |
| NEW World Medical,inc. | 1 | $21 |
| Eyevance Pharmaceuticals LLC | 1 | $21 |
| Tarsus Pharmaceuticals, Inc. | 1 | $16 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Premium Cataract IOLs$1,723
- Hydrus Microstent$1,276
- XEN GLAUCOMA TREATMENT SYSTEM$1,229
- DURYSTA$245
- Rocklatan$244
- OMNI(R) SURGICAL SYSTEM (US)$218
- RXSIGHT CONTACT LENS$212
- RXSIGHT INJECTOR CARTRIDGE$212
- RXSIGHT INJECTOR HANDPIECE$212
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$212
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$212
- VYZULTA$162
- XEN$141
- VEVYE$136
- Rhopressa$124
- TEPEZZA$122
How this compares
$323,128 in reported general payments places this provider in the 95th percentile of 121 ophthalmology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 375 | $170,809 |
| RocklatanNetarsudil Mesylat/Latanoprost | 193 | $99,474 |
| Prednisolone Acetate | 1,680 | $82,393 |
| RestasisCyclosporine | 47 | $41,928 |
| CombiganBrimonidine Tartrate/Timolol | 133 | $41,410 |
| Alphagan PBrimonidine Tartrate | 74 | $31,008 |
| XiidraLifitegrast | 23 | $30,509 |
| Latanoprost | 3,345 | $27,798 |
| Brimonidine Tartrate | 841 | $22,784 |
| VyzultaLatanoprostene Bunod | 46 | $19,677 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,341 | $19,339 |
| Fluorometholone | 201 | $16,138 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 119 | $15,912 |
| RhopressaNetarsudil Mesylate | 38 | $14,265 |
| MoxifloxacinMoxifloxacin Hcl | 704 | $14,134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $169,224 | $285,156629 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $314 | $113,740231 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $222 | $50,18669 claims |
| AlconSimbrinza | $846 | $13,67855 claims |
| NovartisIlevro | $122,809 | $11,20431 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $376 | $4,98322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 121 ophthalmology providers in Nevada.
Other ophthalmology in Henderson
- Judy LiuHenderson$632K
- Rene ZamoraHenderson$216K
- Darrick NeibaurHenderson$36K
- Dan EisenbergHenderson$7K
- Rajy RouweyhaHenderson$3K
- Arshad KhananiReno$45.8M
- Eva LiangLas Vegas$2.2M
- Matthew SwanicLas Vegas$433K
- Nelson LopezLas Vegas$193K
- Kent WellishLas Vegas$185K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.